Thermo Fisher Scientific Launches Integrated Drug Development Platform to Address Industry Fragmentation
核心洞察
Thermo Fisher Scientific (搜索) introduces Accelerator Drug Development, an integrated CDMO and CRO solution designed to streamline pharmaceutical development from early research to commercialization.
The platform addresses critical industry challenges including escalating R&D costs estimated at $1.3-2.8 billion per approved drug and inefficiencies caused by fragmented vendor relationships.
The integrated approach provides single-vendor accountability across clinical research, manufacturing, and supply chain operations, targeting both small biotech companies and large pharmaceutical organizations.
Thermo Fisher Scientific (搜索) has launched Accelerator Drug Development, a comprehensive integrated platform combining contract development and manufacturing organization (CDMO) and clinical research organization (CRO) capabilities to address the growing fragmentation challenges in pharmaceutical development.
The initiative responds to mounting industry pressures, including escalating development costs that recent studies estimate between $1.3 billion to $2.8 billion per approved new drug, inclusive of research failures and time value considerations. Clinical trials represent 70% of total R&D expenditures, making inefficiencies in trial design, execution, supply chain management, and manufacturing coordination major cost drivers.
Addressing Industry Fragmentation
Traditional pharmaceutical development relies on multiple separate vendors for clinical research, laboratories, manufacturing, and supply functions, creating coordination gaps, data silos, and fragmented processes. These systemic challenges compound the escalating costs and regulatory complexities facing pharmaceutical and biotechnology companies.
"Thermo Fisher is transforming drug development and manufacturing processes to support customers as they move critical programmes forward to tackle global health challenges with speed, quality, and efficiency," said Michael Shafer, Executive Vice President and President, Biopharma Services, Thermo Fisher Scientific (搜索). "We connect the steps between discovery and delivery, from early testing and analytical support to clinical research design to trial conduct, clinical supply chain management, manufacturing, and commercial scale-up."
Integrated Solution Architecture
The Accelerator Drug Development platform streamlines CDMO, CRO, and clinical supply services into a single-vendor experience designed to reduce redundancies, enhance data flow, and improve alignment across critical functions. The solution provides centralized oversight through dedicated integrated program management teams coordinating milestone delivery across the entire drug development journey.
Alberto Fernández, Head of Clinical Development Strategy & Innovation at Thermo Fisher Scientific (搜索), emphasized the company's approach to supporting organizations across all major drug modalities and therapeutic areas. With over 32 years of industry experience, including executive leadership positions at GSK and AstraZeneca, Fernández brings extensive expertise in end-to-end clinical development and digital transformation initiatives.
Global Infrastructure and Capabilities
Thermo Fisher's pharmaceutical services operate through approximately 60 locations worldwide, providing integrated solutions across all development phases. The company's CDMO capabilities encompass active pharmaceutical ingredients (APIs), biologics, advanced therapies, formulations, clinical trial solutions, logistics services, commercial manufacturing, and packaging and labeling.
The clinical research services division offers comprehensive capabilities spanning early development through regulatory approval and market access, utilizing patient-centered strategies and AI-enabled solutions to optimize clinical development phases. Services include clinical trial management, analytical and laboratory services, and patient advisory services across multiple therapeutic areas.
Customized Program Management
The platform provides customized resourcing strategies enabling flexible operating models tailored to each customer's team structure. The approach targets pharmaceutical and biotech companies of all sizes, from small and mid-size biotech firms to large pharmaceutical organizations, addressing their unique program needs through coordinated management and transparent collaboration across all development phases.
With annual revenue exceeding $40 billion, Thermo Fisher Scientific (搜索) operates as the world leader in serving science through its comprehensive portfolio of brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.